Watch CNSP. Know when insiders buy.
One email the day a filing lands. Free.
CNSP
CNS Pharmaceuticals, Inc.
5.75
−0.03 −0.52%
USD · close Sep 10
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
26
FLAG · shorts 26
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $8.4MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$16.7MNET CASH —52W 2.13 – 10.57SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$2.7M | −$2.6M | — | -0.38 | −$3.5M | $4K | −$3.5M | Aug 12 |
| Q1 2026 · Mar 31 | — | — | — | −$5M | −$4.9M | — | -7.30 | −$4.6M | $6K | −$4.7M | Aug 12 |
| Q4 2025 · Dec 31derived | — | — | — | −$6M | −$6M | — | -10.15 | −$3.1M | — | — | Mar 31 |
| Q3 2025 · Sep 30 | — | — | — | −$3.3M | −$3.2M | — | -5.76 | −$2.2M | — | — | Nov 14 |
| Q2 2025 · Jun 30 | — | — | — | −$2.4M | −$2.4M | — | -6.42 | −$5.3M | $0 | −$5.3M | Aug 12 |
| Q1 2025 · Mar 31 | — | — | — | −$4.3M | −$4.3M | — | -18.93 | −$3.2M | $0 | −$3.2M | Aug 12 |
| Q4 2024 · Dec 31derived | — | — | — | −$3.2M | −$3.2M | — | 460.87 | −$5.5M | $4K | −$5.5M | Mar 31 |
| Q3 2024 · Sep 30 | — | — | — | −$5.6M | −$5.6M | — | -153.20 | −$6.8M | — | — | Nov 14 |
| Q2 2024 · Jun 30 | — | — | — | −$2.5M | −$2.5M | — | -4049.20 | −$1.7M | — | — | Nov 14 |
| Q1 2024 · Mar 31 | — | — | — | −$3.5M | −$3.5M | — | -1020.48 | −$3.2M | — | — | Nov 14 |
| Q4 2023 · Dec 31derived | — | — | — | −$5.4M | −$5.4M | — | -12306.63 | −$2.5M | $2K | −$2.5M | Mar 31 |
| Q3 2023 · Sep 30 | — | — | — | −$4.5M | −$4.5M | — | -54.14 | −$3.4M | $2K | −$3.4M | Nov 14 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$16M | −$15.9M | — | -35.75 | −$13.8M | $18K | −$13.8M | — | — |
| FY2024 · to Dec 31 | — | — | −$14.9M | −$14.9M | — | -466.89 | −$17.1M | $4K | −$17.1M | — | — |
| FY2023 · to Dec 31 | — | — | −$18.9M | −$18.9M | — | -12509.11 | −$14.1M | $4K | −$14.1M | — | — |
| FY2022 · to Dec 31 | — | — | −$15.3M | −$15.3M | — | -11.22 | −$10.6M | $4K | −$10.6M | — | — |
| FY2021 · to Dec 31 | — | — | −$14.5M | −$14.5M | — | -16.50 | −$13.5M | $6K | −$13.5M | — | — |
| FY2020 · to Dec 31 | — | — | −$9.5M | −$9.5M | — | -0.57 | −$7.3M | $18K | −$7.3M | — | — |
Every number comes from CNS Pharmaceuticals, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.